Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase II study of SHR-1918 in homozygous familial hypercholesterolemia
CTR20232534Phase 2Completed
- Sponsor
- Beijing Shengdi Pharmaceutical
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1918 in familial hypercholesterolemia (FH), sponsored by Beijing Shengdi Pharmaceutical. Started Aug 2023; status: completed.
02
Drugs
SHR-1918
03
Conditions
familial hypercholesterolemia (FH)
Beyond the preview
Go deeper on CTR20232534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232534.